Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

4.425 -0.135 (-2.96%)
Streaming Delayed Price Updated: 12:06 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
News headline image
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users. 
Via MarketBeat
News headline image
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
News headline image
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
News headline image
Decoding 4 Analyst Evaluations For Altimmune ↗
 
Via Benzinga
News headline image
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024 ↗
ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks for the Long-Term: August 2024 ↗
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. 
Via InvestorPlace
News headline image
The 7 Best Under $10 Stocks to Buy in August 2024 ↗
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10. 
Via InvestorPlace
News headline image
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year ↗
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
News headline image
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
News headline image
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
News headline image
Forecasting The Future: 5 Analyst Projections For Altimmune ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Altimmune? ↗
 
Via Benzinga
News headline image
3 Undervalued Biotech Stocks With Breakout Potential ↗
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace
News headline image
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio ↗
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on. 
Via InvestorPlace
News headline image
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics ↗
Both competitors have promising lead programs, and enough cash, too. 
Via The Motley Fool
News headline image
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K ↗
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
News headline image
The 7 Best Under $10 Stocks to Buy in July 2024 ↗
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
News headline image
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics ↗
While their share prices have traveled different paths recently, the similarity between the two companies is striking. 
Via The Motley Fool
News headline image
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy ↗
The market for weight loss medicines keeps getting hotter and hotter. 
Via The Motley Fool
News headline image
The 3 Smartest Biotech Stocks to Buy With $5K Right Now ↗
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. 
Via InvestorPlace
News headline image
Why Are Altimmune Shares Trading Lower Wednesday? ↗
Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer. 
Via Benzinga
News headline image
Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
News headline image
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms ↗
Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers. 
Via InvestorPlace
News headline image
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings ↗
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
News headline image
Altimmune Stock Is Rising Monday: What's Driving The Action? ↗
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes... 
Via Benzinga
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Stocks Under $10 Set to Quadruple by 2025: June Edition ↗
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst. 
Via InvestorPlace
News headline image
3 Stocks Quietly Preparing for a 10X Surge: June Edition ↗
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.